ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

PURPOSE: EML4–ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance limits their ultimate efficacy. Thus, a better understanding of resistance mech...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Heuckmann, Johannes M., Hölzel, Michael, Sos, Martin L., Heynck, Stefanie, Balke-Want, Hyatt, Koker, Mirjam, Peifer, Martin, Weiss, Jonathan, Lovly, Christine M., Grütter, Christian, Rauh, Daniel, Pao, William, Thomas, Roman K.
Format: Artigo
Langue:Inglês
Publié: 2011
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382103/
https://ncbi.nlm.nih.gov/pubmed/21948233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1648
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires